Prion Disease Cure Roadmap

Prion Disease Cure Roadmap

Overview

Prion Disease Cure Roadmap provides a comprehensive framework for therapeutic development for prion diseases, also known as transmissible spongiform encephalopathies (TSEs). Prion diseases are unique in that they are caused by a protein-only infectious agent — the prion protein (PrP^Sc) — which is an aggregated, misfolded conformer of the normal cellular prion protein (PrP^C)[@prusiner1998].

Prion diseases affect both humans and animals:

• Human: Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), kuru, variant CJD (vCJD), GSS syndrome
• Animal: Bovine spongiform encephalopathy (BSE), scrapie (sheep), chronic wasting disease (CWD) (deer, elk)

The fundamental challenge is that prions propagate by template-driven conformational conversion of normal PrP^C to the infectious PrP^Sc form, and this process is inherently self-reinforcing — making it exceptionally difficult to interrupt.

Current Therapeutic Landscape

Approved Treatments

No disease-modifying or curative treatments are approved for any human prion disease.

Palliative care focuses on:

• Symptom management (myoclonus, insomnia, dysphagia)
• Nutritional support
• Prevention of aspiration pneumonia

Historical Therapeutic Attempts

...

Prion Disease Cure Roadmap

Overview

Prion Disease Cure Roadmap provides a comprehensive framework for therapeutic development for prion diseases, also known as transmissible spongiform encephalopathies (TSEs). Prion diseases are unique in that they are caused by a protein-only infectious agent — the prion protein (PrP^Sc) — which is an aggregated, misfolded conformer of the normal cellular prion protein (PrP^C)[@prusiner1998].

Prion diseases affect both humans and animals:

• Human: Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), kuru, variant CJD (vCJD), GSS syndrome
• Animal: Bovine spongiform encephalopathy (BSE), scrapie (sheep), chronic wasting disease (CWD) (deer, elk)

The fundamental challenge is that prions propagate by template-driven conformational conversion of normal PrP^C to the infectious PrP^Sc form, and this process is inherently self-reinforcing — making it exceptionally difficult to interrupt.

Current Therapeutic Landscape

Approved Treatments

No disease-modifying or curative treatments are approved for any human prion disease.

Palliative care focuses on:

• Symptom management (myoclonus, insomnia, dysphagia)
• Nutritional support
• Prevention of aspiration pneumonia

Historical Therapeutic Attempts

| Drug | Mechanism | Trial Result |
|------|-----------|--------------|
| Quinacrine | Anti-prion activity in cell models | No clinical benefit (CJD) |
| Pentosan polysulfate | Prion binding | No survival benefit |
| Amphotericin B | Anti-prion | No benefit |
| Doxycycline | Anti-aggregation | Mixed results |
| Flupirtine | Neuroprotection | No benefit |

Current Clinical Trials

• PRN2008 (ProMab): Anti-PrP monoclonal antibody in early-phase trials
• Anle305b (Universität Tübingen): Prion aggregation inhibitor in preclinical/Phase 1

Therapeutic Target Map

1. Prion Protein Conversion Inhibitors

The core therapeutic strategy is preventing the conversion of PrP^C to PrP^Sc:

Approaches:

• Small molecules: Polyanionic compounds, aromatic heterocycles
• Antibodies: Anti-PrP monoclonal antibodies (blocking conversion)
• Peptide-based: PrP-derived sequences that block template

2. PrP^Sc Clearance

Once prions have formed, removing them requires:

• Immunotherapy: Anti-PrP antibodies to clear existing aggregates
• Autophagy enhancers: Rapamycin, trehalose to boost protein clearance
• Protein degradation: PROTACs targeting PrP

3. Neuroprotection

Since prion toxicity involves multiple pathways:

• ER stress inhibitors: Salubrinal, ISRIB
• Mitochondrial protectants: CoQ10, SS-31
• Anti-inflammatory: Minocycline (cautiously)
• Synaptic preservation: BDNF, synaptic stabilizers

4. Gene Therapy

• PRNP knockdown: ASO or siRNA to reduce PrP^C expression
• PRNP editing: CRISPR-based approaches
• Resistance mutations: Identify protective PRNP variants

Biomarker Development

Diagnostic Biomarkers

| Biomarker | Target | Status |
|-----------|--------|--------|
| 14-3-3 protein | CSF | Widely used, moderate specificity |
| Tau protein | CSF | Elevated in CJD |
| RT-QuIC | CSF/tissue | High sensitivity/specificity |
| Real-time quaking-induced conversion (RT-QuIC) | Nasal brush, skin | Emerging |
| PrP^Sc detection | Tissue | Gold standard (post-mortem) |

Disease Progression Biomarkers

• Neurofilament light chain (NfL): Blood/CSF marker of neurodegeneration
• Neurogranin: Synaptic damage
• YKL-40: Microglial activation

Pre-Symptomatic Detection

For genetic prion disease (PRNP mutations):

• Presymptomatic genetic testing available
• Biomarker monitoring in carriers (NfL, RT-QuIC)
• Intervention timing critical — treat before symptoms

Clinical Trial Design

Challenges

Rapid disease progression: CJD median survival 4-6 months

Diagnostic uncertainty: Require definite/probable CJD

Heterogeneous disease: Sporadic, genetic, iatrogenic, variant

Limited patient numbers: Rare disease

No validated surrogate endpoints

Enrichment Strategies

• Target pre-symptomatic genetic carriers
• Early-stage symptomatic patients
• Exclude rapidly progressive cases
• Require positive RT-QuIC

Outcome Measures

| Domain | Measure | Notes |
|--------|---------|-------|
| Survival | Primary: time to death | Challenging with rapid progression |
| Cognition | MMSE, CDR | Floor effects |
| Motor | MRS, neurological exam | Myoclonus tracking |
| Biomarker | NfL, tau, RT-QuIC | Surrogate potential |

Trial Designs

• Adaptive platform trials: Multiple agents simultaneously
• Master protocol: Umbrella trials for CJD subtypes
• Pre-symptomatic trials: In genetic carriers

Research Gaps and Priorities

Critical Gaps

Prion strain diversity — how different strains cause different phenotypes

Cell-to-cell transmission mechanism — how prions spread between neurons/glia

Neurotoxic species identification — which PrP^Sc form causes damage

Biomarker validation — for early detection and treatment response

Combination therapy — synergy between conversion inhibitors and clearance

Cross-References

• [Prion Disease](/diseases/prion-disease)
• [Prion Knowledge Gaps](/gaps/prion-disease)
• [Prion Strain Diversity and Selective Vulnerability in CJD](/experiments/prion-strain-diversity-cjd)
• [Pre-Symptomatic Detection in Genetic Prion Disease](/experiments/pre-symptomatic-detection-genetic-prion)
• [Prion Propagation Mechanism](/experiments/prion-propagation-mechanism-cell-to-cell)
• [Anti-Prion Therapeutic Development](/experiments/anti-prion-therapeutic-development-hts)
• [Experiment Priority Index](/experiments/experiment-priority-index)

Projected Therapeutic Timeline

Near-Term (2025-2028)

Anti-PrP antibodies — Phase 1/2 results (PRN2008)

Prion aggregation inhibitors — early trials (Anle305b)

RT-QuIC optimization — for treatment response

Mid-Term (2028-2032)

First disease-modifying therapy — likely immunotherapy combination

Genetic carrier intervention — pre-symptomatic treatment protocols

Biomarker-driven patient selection — for clinical trials

Long-Term (2032-2040)

Prevention in genetic carriers — early intervention before conversion

Cure through gene therapy — PRNP editing or knockdown

Combination approaches — inhibitors + clearance + neuroprotection

Cross-References